The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Revisiting the optimal neoadjuvant immunotherapy regimen in resectable stage III melanoma based on the interferon gamma signature: A pooled analysis.
 
Minke W. Lucas
No Relationships to Disclose
 
Petros Dimitriadis
Stock and Other Ownership Interests - Signature oncology
 
Irene L.M. Reijers
Patents, Royalties, Other Intellectual Property - Drs. Reijers reports financial interest in Signature Oncology, and will receive some possible revenues if the IFN-y signature is being developed as clinical companion diagnostic.
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; QBiotics; Roche
 
Elisa A. Rozeman
No Relationships to Disclose
 
Judith M. Versluis
No Relationships to Disclose
 
Alexander Chan Chi Huang
Consulting or Advisory Role - Immunai
Research Funding - Bristol-Myers Squibb
 
Sten Cornelissen
No Relationships to Disclose
 
Annegien Broeks
No Relationships to Disclose
 
Richard A. Scolyer
Employment - Royal Prince Alfred Hospital
Honoraria - GlaxoSmithKline; Harvard Medical School; Wake Forest School of Medicine
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb GesmbH (Austria); Bristol-Myers Squibb SA (Switzerland); Evaxion Biotech; GlaxoSmithKline; Merck Sharp & Dohme; metaoptima; MSD Sharp & Dohme (Australia) Pty Limited; Myriad Genetics; NeraCare GmbH; Novartis; Novartis; Novartis; Novartis; Provectus Biopharmaceuticals; QBiotics; Roche
Research Funding - Melanoma Research Alliance (MRA); National Health and Medical Research Council; National Health and Medical Research Council; National Health and Medical Research Council; The Ainsworth Foundation (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
(OPTIONAL) Uncompensated Relationships - Melanoma Institute Australia
 
Tara C. Mitchell
Consulting or Advisory Role - Bristol-Myers Squibb; GigaGen; Instil Bio; Merck; OncoSec
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst)
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Innovent Biologics; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Provectus; QBiotics; Regeneron
 
Christian U. Blank
Stock and Other Ownership Interests - Immagene
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Third Rock Ventures
Research Funding - 4SC (Inst); Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - WO 2021/177822 A1
Expert Testimony - Freshfields Bruckhaus Deringer
Travel, Accommodations, Expenses - Bristol-Myers Squibb